We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-18.69%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$714M
AUM Growth
-$199M
Cap. Flow
+$8.81M
Cap. Flow %
1.23%
Top 10 Hldgs %
30.92%
Holding
97
New
3
Increased
39
Reduced
32
Closed
12

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$10.8M
2
ABBV icon
AbbVie
ABBV
+$10.2M
3
CVS icon
CVS Health
CVS
+$8M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.61M
5
UNH icon
UnitedHealth
UNH
+$6.05M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$10.3M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.1M
4
HUM icon
Humana
HUM
+$7.42M
5
BDX icon
Becton Dickinson
BDX
+$5.06M

Sector Composition

Rank Sector Weight
1 Healthcare 96.22%
2 Energy 0.06%
3 Technology 0.03%
4 Financials 0.02%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
26
Iovance Biotherapeutics
IOVA
$2.87B
$10.9M 1.53%
365,000
-110,000
-23% -$2.92M
EW icon
27
Edwards Lifesciences
EW
$53.7B
$10.8M 1.51%
171,000
+57,000
+50% +$4.11M
CNC icon
28
Centene
CNC
$32.7B
$10.4M 1.46%
175,000
+35,000
+25% +$2.12M
ARNA
29
DELISTED
Arena Pharmaceuticals Inc
ARNA
$10.1M 1.41%
240,000
+20,000
+9% +$917K
MRTX
30
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.99M 1.4%
130,000
+5,000
+4% +$448K
SGEN
31
DELISTED
Seagen Inc. Common Stock
SGEN
$9.81M 1.37%
85,000
-35,000
-29% -$3.88M
AERI
32
DELISTED
Aerie Pharmaceuticals
AERI
$9.72M 1.36%
720,000
+20,000
+3% +$379K
XNCR icon
33
Xencor
XNCR
$1.63B
$8.97M 1.26%
300,325
-9,675
-3% -$321K
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.72M 1.22%
567,534
+67,534
+14% +$1.47M
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$29.4B
$8.71M 1.22%
80,000
+19,285
+32% +$2.23M
KYNB
36
Kyntra Bio
KYNB
$29.1M
$8.69M 1.22%
10,000
-1,000
-9% -$994K
LIVN icon
37
LivaNova
LIVN
$4.22B
$8.6M 1.2%
190,000
-10,000
-5% -$648K
MYOK
38
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.44M 1.18%
180,000
-30,000
-14% -$1.92M
HCA icon
39
HCA Healthcare
HCA
$90.2B
$8.09M 1.13%
90,000
+20,000
+29% +$2.59M
ZBH icon
40
Zimmer Biomet
ZBH
$18.6B
$8.09M 1.13%
+82,400
New +$10.8M
IMMU
41
DELISTED
Immunomedics Inc
IMMU
$7.95M 1.11%
590,000
-110,000
-16% -$1.85M
BIIB icon
42
Biogen
BIIB
$30.3B
$7.91M 1.11%
25,000
+5,000
+25% +$1.52M
COO icon
43
Cooper Companies
COO
$15B
$6.62M 0.93%
96,000
+16,000
+20% +$1.3M
XLRN
44
DELISTED
Acceleron Pharma
XLRN
$6.29M 0.88%
70,000
-30,000
-30% -$2.33M
EXAS
45
DELISTED
Exact Sciences
EXAS
$6.05M 0.85%
104,300
-2,700
-3% -$219K
MGNX icon
46
MacroGenics
MGNX
$259M
$5.82M 0.82%
1,000,000
-60,000
-6% -$545K
ALKS icon
47
Alkermes
ALKS
$8.27B
$5.75M 0.81%
399,000
+29,000
+8% +$518K
OMCL icon
48
Omnicell
OMCL
$1.71B
$5.65M 0.79%
86,095
-8,905
-9% -$710K
SILK
49
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$5.51M 0.77%
175,000
-34,381
-16% -$1.38M
EPZM
50
DELISTED
Epizyme, Inc
EPZM
$5.43M 0.76%
350,000
-75,000
-18% -$1.61M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2020 Portfolio in Review

As of Q1 2020, Rhenman & Partners Asset Management held 97 positions worth $714M, down 22% from $913M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management's Q1 2020 filing shows 3 new, 39 increased, 32 reduced and 12 closed positions. Its largest new stake was Zimmer Biomet: 82,400 shares worth $8.09M. The largest sale was Dermira, Inc., an estimated $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Energy and Technology.

  • Rhenman & Partners Asset Management's largest Q1 2020 buy was Zimmer Biomet: 82,400 shares worth $8.09M.
  • Rhenman & Partners Asset Management added most to AbbVie in Q1 2020, an estimated $10.2M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $10.3M.
  • Rhenman & Partners Asset Management fully exited Dermira, Inc. in Q1 2020, selling an estimated $12.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $714M portfolio in Q1 2020.
  • Rhenman & Partners Asset Management opened 3 new positions and closed 12 in Q1 2020.
  • Rhenman & Partners Asset Management's portfolio value fell 22% quarter-over-quarter to $714M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2020, filed 16 Apr 2020.